ArticlemBio2026
Opposing roles of deubiquitinases in the regulation of IRF7 transcriptional activity.
Article in mBio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Virus infection rapidly induces the production and secretion of interferons (IFNs), which amplify the antiviral responses in infected and neighboring uninfected cells. IFN regulatory factor 7 (IRF7), the "master transcription factor," is pivotal in IFN induction, particularly in myeloid cells. Ubiquitination of IRF7 is essential for its transcriptional activation; however, the underlying molecular mechanisms remain poorly understood. We hypothesized that deubiquitinases (DUBs) act as endogenous regulators of IRF7 activity, and conducted a genetic screen using an siRNA library of human DUBs. The screen identified USP2 as a positive regulator and OTUD5 as a negative regulator of IRF7 activity. OTUD5, an inducible DUB, interacted with IRF7 and inhibited its K63-linked ubiquitination, thereby suppressing IRF7 activation. Conversely, USP2 promoted IRF7 activity by binding to IRF7 and removing K27-linked ubiquitin chains, which we found to be inhibitory. Specifically, K27-linked ubiquitination impeded phosphorylation of IRF7, a critical step for its activation. Collectively, our independent lines of investigation, coupled with genetic screens and mechanistic studies, uncovered USP2 and OTUD5 as novel modulators of IRF7 function, providing novel insights into the regulation of antiviral immunity. IMPORTANCE: IFN regulatory factor 7 (IRF7) is a central protein that launches type I interferon responses, and its timely activation is essential for antiviral immunity. Our study uncovers a mechanism by which IRF7 activation is controlled by enzymes that specifically remove small molecular tags, known as ubiquitin, from proteins. Through a focused screen, we identified two enzymes with opposing roles in modulating IRF7 activity. OTUD5, one of these enzymes, suppresses IRF7 activity by removing a ubiquitin tag that is essential for its transcriptional function. In contrast, USP2, the other enzyme, activates IRF7 by removing a ubiquitin tag that is inhibitory to IRF7 functions. These findings reveal previously unrecognized layers of IRF7 regulation and highlight how these enzymes can be targeted therapeutically in diseases driven by abnormal IRF7 functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.